#USA #Chicago #Innovent Biologics #oncology #Biopharmaceutical

Innovent Biologics to Present Preclinical Data at AACR 2025

Innovent Biologics, a prominent entity in the biopharmaceutical realm, is poised to share its latest preclinical findings at the annual American Association for Cancer Research (AACR) meeting from April 25 to April 30, 2025, in Chicago. The data highlighted will encompass innovative bispecific antibodies and antibody-drug conjugates (ADCs), pivotal components in the company’s oncology research pipeline.

Located at the forefront of medical advancement, Innovent is set to display a range of promising therapies aimed at combating various major diseases, such as cancer, cardiovascular, autoimmune conditions, and ocular diseases. This exposition will signify a substantial contribution towards advancing cancer treatment, particularly for solid tumors that have thus far shown resistance against existing immune checkpoint inhibitors.

Research Highlights

Among the noteworthy presentations at the AACR meeting, the following will take center stage:

• - IAR037 – A Novel CD40/PD-L1 Bispecific Antibody: Targeting advanced solid tumors, this groundbreaking therapy aims to show efficacy in patients who have not responded to traditional immune checkpoint therapies. This preclinical data is scheduled for presentation on April 28.

• - IBI3010 – FRα Targeting ADC: Focused on tumors expressing folate receptor alpha, IBI3010 offers a novel approach through a biparatopic mechanism. This particular research will be revealed on the same day as IAR037, showcasing its potential in tackling unresponsive cancers.

• - IBI3019 – First-in-Class Tri-Specific Antibody: Set to be presented on April 29, this innovative treatment targets colorectal cancer with an emphasis on a strong safety profile along with effective outcomes in preclinical models.

• - IBI3026 – Anti-PD-1/IL-12 Fusion Protein: This promising new immuno-oncology therapy seeks to invigorate immune response, with the aim of promoting T and NK cell activity against tumor cells. Presentation is scheduled for April 28.

• - IBI3014 – TROP2xPD-L1 Bi-Specific ADC: This unique agent integrates various therapeutic mechanisms into a single molecule and reflects promising results in preclinical trials. Its presentation will occur on April 27.

These studies not only reinforce Innovent's scientific capabilities but also reflect its ongoing commitment to developing transformative therapeutic options for patients globally. Dr. Kaijie He, the Vice President of Innovent, highlighted that the company’s ongoing research aims not just to be innovative but to optimize targeted therapy mechanisms, thereby creating solutions for complex diseases that affect countless individuals.

Innovent’s Vision and Mission

Founded in 2011, Innovent Biologics is dedicated to empowering patients worldwide with affordable, high-quality biopharmaceutical products. This dedication manifests through the discovery and development of groundbreaking medications that cater to some of the most stubborn diseases. Currently, Innovent has 15 products in the market along with several candidates in the pipeline, including three new drug applications undergoing regulatory review.

Their collaborations with more than 30 international healthcare corporations underscore their standing in the global market. Innovent's guiding principle, “Start with Integrity, Succeed through Action,” speaks volumes of their commitment to maintaining high industry standards and delivering innovative therapeutic options.

As the AACR 2025 draws near, the anticipation surrounding Innovent’s preclinical data presentations brings hope for the future of oncology treatments, reinforcing the need for continuous research and development in the fight against cancer and other major diseases.

For more detailed information about Innovent's groundbreaking research and initiatives, please visit their official website: www.innoventbio.com.